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The OSCAR study was a multicenter, prospective randomized
open-label blinded end-point study of 1164 Japanese elderly
hypertensive patients comparing the efficacy of angiotensin
II receptor blocker (ARB) uptitration to an ARB plus calcium
channel blocker (CCB) combination. In this prospective study,
we performed prespecified subgroup analysis according to
baseline estimated glomerular filtration rate (eGFR) with
chronic kidney disease (CKD) defined as an eGFRo60ml/min
per 1.73m2. Blood pressure was lower in the combined
therapy than in the high-dose ARB cohort in both groups
with and without CKD. In patients with CKD, significantly
more primary events (a composite of cardiovascular events
and noncardiovascular death) occurred in the high-dose ARB
group than in the combination group (30 vs. 16, respectively,
hazard ratio 2.25). Significantly more cerebrovascular and
more heart failure events occurred in the high-dose ARB
group than in the combination group. In patients without
CKD, however, the incidence of primary events was similar
between the two treatments. The treatment-by-subgroup
interaction was significant. Allocation to the high-dose ARB
was a significant independent prognostic factor for primary
events in patients with CKD. Thus, the ARB plus CCB combina-
tion conferred greater benefit in prevention of cardiovascular
events in patients with CKD compared with high-dose ARB
alone. Our findings provide new insight into the antihyper-
tensive strategy for elderly hypertensive patients with CKD.
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Chronic kidney disease (CKD), manifested by decreased
glomerular filtration rate (GFR), is a worldwide public health
problem, and an older population has a higher prevalence of
CKD.1–5 A large amount of evidence shows that decreased
GFR is an independent risk factor for cardiovascular events
and all-cause mortality in the general population1,2,4–6 and
high-risk populations such as the elderly,3 as well as in
patients with hypertension,7 diabetes,8 heart failure,9 or
myocardial infarction.10 The National Kidney Foundation
Task Force11 and a statement from the American Heart
Association Councils12 have recommended that patients with
CKD should be considered as a high-risk group for subse-
quent cardiovascular events and that treatment recommen-
dation based on cardiovascular risk stratification should take
into account the highest-risk status of patients with CKD.
It has been established that the renin–angiotensin system
(RAS) has a pivotal role in the pathophysiology of CKD and
cardiovascular disease. Inhibition of RAS by angiotensin II
receptor blockers (ARBs) or angiotensin-converting enzyme
inhibitors confers cardiovascular protection in both
diabetic13,14 and nondiabetic hypertensive patients with
CKD,7,15 and is regarded as the first-line therapeutic strategy
for CKD in Western countries16,17 and Japan.18 Furthermore,
previous evidence indicates that uptitration of an ARB
provides greater suppression of renal events in hypertensive
patients with diabetic nephropathy19 and greater reduction of
cardiovascular events in heart failure patients20 compared with
lower dose of ARB, thereby showing the benefit of high-dose
ARB therapy in prevention of cardiovascular and renal events.
http://www.kidney-international.org c l i n i ca l t r i a l
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On the other hand, the combination of ARB and calcium
channel blocker (CCB) is recommended as one of the
preferred combination therapies for the general hypertensive
population.16–18 However, it remains to be elucidated which
antihypertensive strategy is more effective for the prevention
of cardiovascular morbidity and mortality in high-risk
subjects with CKD compared with those without CKD at
baseline; that is, is ARB plus CCB combination therapy or
high-dose ARB therapy more effective?
We conducted the OlmeSartan and Calcium Antagonists
Randomized (OSCAR) study comparing the preventive effect
of ARB plus CCB combination therapy versus high-dose ARB
therapy on cardiovascular morbidity and mortality in
Japanese elderly hypertensive patients with baseline cardio-
vascular disease and/or type 2 diabetes, and have recently
reported the principal results of the OSCAR study.21 In the
present study, to determine whether CKD might influence
the relative effectiveness of ARB plus CCB combination
versus high-dose ARB in the prevention of cardiovascular
morbidity and mortality, we performed a subgroup analysis
of the OSCAR study according to baseline estimated GFR
(eGFR), which we had prespecified as described in our
protocol paper.22
RESULTS
Categorization of patients according to baseline eGFR
Eighty-six patients were excluded from the present analysis
because no serum creatinine value at baseline was available.
As a result, 1078 patients of a total of 1164 patients originally
enrolled in the OSCAR study were included in the present
analysis (Table 1). The number of patients with an eGFR of
o60ml/min per 1.73mm2 (defined as patients with CKD)
was 353; of these, 334 (94.6%) patients had an eGFR of
30–59ml/min per 1.73mm2 and 19 patients (5.4%) had an
eGFR o30ml/min per 1.73mm2. The number of patients
having an eGFRX60ml/min per 1.73mm2 (patients without
CKD) was 725; of these, 629 (86.8%) patients had an eGFR of
60–89ml/min per 1.73mm2 and 96 patients (13.2%) had an
eGFR X90ml/min per 1.73mm2.
Demographic and baseline characteristics of patients with
and without CKD
Importantly, there was no significant difference regarding
any of the baseline characteristics between the patients
(n¼ 1078) included in the present analysis and total patients
(n¼ 1164)21,22 originally enrolled in the OSCAR study.
As shown in Table 1, eGFR (mean±s.d.) in patients with
and without CKD was 47.8±9.1 and 76.7±14.4ml/min per
1.73mm2, respectively (Po0.0001 between the two groups).
Compared with patients without CKD, patients with CKD
were older, had higher serum creatinine, and lower serum
high-density lipoprotein cholesterol; a lower proportion of
them had a history of previous antihypertensive agents and
a higher proportion had a history of antiplatelet agents.
In patients with CKD (Table 1), baseline characteristics
were well balanced between high-dose ARB and ARB plus
CCB treatment groups, except for a slight difference in body
mass index between the two groups (24.2±3.4 vs. 23.5±
3.0 kg/m2, P¼ 0.03). In patients without CKD (Table 1),
there was no significant difference between the two treatment
groups in any of the baseline characteristics.
Table 2 shows that a higher proportion of patients with
CKD had cardiovascular disease at baseline compared with
those without CKD (80.5 vs. 66.9%, Po0.0001), whereas
a slightly lower proportion of them had type 2 diabetes at
baseline (49.0 vs. 55.9%, P¼ 0.03).
As shown in Table 2, in patients with CKD and without
CKD, no significant difference was found between the two
treatment groups in proportion of patients with previously
existing cardiovascular disease or type 2 diabetes, except for
a slight difference between the treatment groups in the
percentage of previous stroke in patients without CKD.
Blood pressure (BP) during follow-up period
Table 3 shows the number and percentage of patients who
received additional antihypertensive drug(s) in the two treat-
ment groups in the subgroups with CKD or without CKD,
throughout the follow-up period. In all groups, diuretics,
b-blockers, and a-blockers were mainly prescribed as addi-
tional antihypertensive medications, and diuretics were the
most prescribed among all additional antihypertensive drugs.
The percentage of patients who received these additional
antihypertensive drugs was greater in the high-dose ARB
group than in the ARB plus CCB combination group, in both
the subgroups with CKD and that without CKD.
In patients with CKD (Figure 1a), systolic BP of the ARB
plus CCB combination group was lower than that of the
high-dose ARB group throughout the follow-up period, and
the mean difference in systolic BP between the groups during
follow-up period was 3.7mmHg (P¼ 0.0051). In patients
without CKD (Figure 1b), both systolic BP and diastolic BP
were lower in the ARB plus CCB combination group than in
the high-dose ARB group, and the mean difference in systolic
BP and diastolic BP between the groups was 2.2mmHg
(P¼ 0.0039) and 1.8mmHg (P¼ 0.0013), respectively.
The proportion of patients who achieved target BP of
o140/90mmHg was significantly higher in the ARB plus
CCB combination group than in the high-dose ARB group,
both in patients with CKD (77.3 vs. 60.2%, P¼ 0.0005) and
those without CKD (75.7 vs. 67.8%, P¼ 0.0174).
Incidence of primary outcome events in patients with or
without CKD
Figure 2 indicates the incidence of primary outcome events in
the high-dose ARB and ARB plus CCB combination groups
in patients with CKD and without CKD. There was a
significant interaction between the subgroup of patients with
CKD and those without CKD for the incidence of primary
outcome events, and the treatment-by-subgroup interaction
was statistically significant (P¼ 0.0293 for interaction).
In patients with CKD (Figure 2a), 30 patients (16.6%; 63.7
per 1000 patient-years) of 181 patients assigned to high-dose
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Table 1 | Baseline characteristics
Overall CKD (þ ) CKD ( )
Total patients
(n¼ 1078)
CKD (þ )
(n¼ 353)
CKD ( )
(n¼ 725) P-value
High-dose ARB
(n¼ 181)
ARBþCCB
(n¼ 172)
High-dose ARB
(n¼ 354)
ARBþCCB
(n¼ 371)
eGFR (ml/min per 1.73m2) 67.2±18.7 47.8±9.1 76.7±14.4 o0.0001 47.3±8.9 48.3±9.3 76.4±13.9 76.9±14.8
Age (years) 73.7±5.4 75.5±5.2 72.8±5.3 o0.0001 75.2±5.1 75.8±5.4 73.0±5.4 72.7±5.3
Male, n (%) 477 (44.3) 167 (47.3) 310 (42.8) 0.16 80 (44.2) 87 (50.6) 157 (44.4) 153 (41.2)
BMI (kg/m2) 24.1±3.6 23.9±3.2 24.2±3.7 0.17 24.2±3.4 23.5±3.0a 24.3±3.8 24.1±3.7
BMI X25kg/m2, n (%) 403 (37.5) 118 (33.4) 285 (39.4) 0.06 67 (37.0) 51 (29.7) 144 (40.8) 141 (38.1)
Systolic BP (mmHg) 158.0±11.9 158.9±12.0 157.5±11.8 0.07 158.9±12.8 158.9±11.2 158.3±12.3 156.7±11.3
Diastolic BP (mmHg) 84.6±9.8 84.8±9.7 84.6±9.8 0.79 85.0±9.8 84.5±9.7 84.8±9.8 84.4±9.8
Heart rate (b.p.m) 73±10 73±10 73±10 0.76 74±10 73±10 74±10 73±9
Hyperlipidemia, n (%) 528 (49.0) 177 (50.1) 351 (48.4) 0.59 96 (53.0) 81 (47.1) 173 (48.9) 178 (48.0)
Current smoker, n (%) 107 (9.9) 26 (7.4) 81 (11.2) 0.05 16 (8.9) 10 (5.8) 43 (12.2) 38 (10.2)
Current alcohol intake, n (%) 350 (32.6) 125 (35.7) 225 (31.0) 0.12 55 (30.7) 70 (40.9) 114 (32.2) 111 (29.9)
Serum values
Creatinine (mg/dl) 0.8±0.3 1.1±0.3 0.7±0.1 o0.0001 1.1±0.3 1.1±0.3 0.7±0.1 0.7±0.1
Potassium (mmol/l) 4.3±0.5 4.4±0.5 4.3±0.4 o0.0001 4.4±0.4 4.5±0.5 4.3±0.4 4.3±0.4
Total cholesterol (mg/dl) 199±35 195±35 200±35 0.03 196±36 194±35 198±34 203±36
HDL cholesterol (mg/dl) 56.6±15.2 53.9±15.2 57.9±15.0 o0.0001 54.9±17.0 52.9±13.0 56.8±14.6 58.9±15.3
Fasting plasma glucose (mg/dl) 117±44 116±46 117±43 0.72 119±48 113±45 120±48 115±38
Casual plasma glucose (mg/dl) 145±59 140±56 147±60 0.25 138±54 144±59 144±55 150±64
Previous antihypertensive treatment, n (%)
No. of agents
0 300 (27.8) 66 (18.7) 234 (32.3) o0.0001 33 (18.2) 33 (19.2) 115 (32.5) 119 (32.1)
1 473 (43.9) 163 (46.2) 310 (42.8) 83 (45.9) 80 (46.5) 150 (42.4) 160 (43.1)
2 253 (23.5) 104 (29.5) 149 (20.6) 52 (28.7) 52 (30.2) 72 (20.3) 77 (20.8)
X3 52 (4.8) 20 (5.7) 32 (4.4) 13 (7.2) 7 (4.1) 17 (4.8) 15 (4.0)
Oral glucose-lowering agents, n (%) 417 (38.7) 134 (38.0) 283 (39.0) 0.73 71 (39.2) 63 (36.6) 144 (40.7) 139 (37.5)
Insulin treatment, n (%) 68 (6.3) 24 (6.8) 44 (6.1) 0.64 12 (6.6) 12 (7.0) 19 (5.4) 25 (6.7)
Lipid-lowering agents, n (%) 399 (37.0) 133 (37.7) 266 (36.7) 0.75 66 (36.5) 67 (39.0) 134 (37.9) 132 (35.6)
Antiplatelet agents, n (%) 343 (31.8) 142 (40.2) 201 (27.7) o0.0001 65 (35.9) 77 (44.8) 103 (29.1) 98 (26.4)
Abbreviations: ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; eGFR, estimated
glomerular filtration rate; HDL, high-density lipoprotein.
Data are mean±s.d. for continuous variables and number (%) for categorical variables. P-value was calculated using t-tests for continuous variables and w2 tests for
categorical variables. CKD (þ ), patients with CKD (with eGFR of o60 ml/min per 1.73m2) at baseline; CKD ( ), patients without CKD (with eGFR of X60 ml/min per
1.73m2) at baseline; High-dose ARB, patients allocated to high-dose ARB therapy; ARBþCCB, patients allocated to ARBþCCB combination therapy.
a
P¼ 0.03 versus high-dose ARB.
Table 2 | Baseline cardiovascular disease and type 2 diabetes of overall patients and patients with or without CKD
Overall CKD (þ ) CKD ( )
Total patients
(n¼ 1078)
CKD (þ )
(n¼ 353)
CKD ( )
(n¼ 725) P-value
High-dose ARB
(n¼ 181)
ARBþCCB
(n¼ 172)
High-dose ARB
(n¼ 354)
ARBþCCB
(n¼ 371)
Previous cardiovascular disease, n (%) 769 (71.3) 284 (80.5) 485 (66.9) o0.0001 149 (82.3) 135 (78.5) 238 (67.2) 247 (66.6)
Stroke 193 (17.9) 74 (21.0) 119 (16.4) 0.07 37 (20.4) 37 (21.5) 69 (19.5) 50 (13.5)a
Transient ischemic attack 52 (4.8) 27 (7.7) 25 (3.5) 0.003 16 (8.8) 11 (6.4) 9 (2.5) 16 (4.3)
Asymptomatic cerebrovascular disease 196 (18.2) 58 (16.4) 138 (19.0) 0.3 33 (18.2) 25 (14.5) 68 (19.2) 70 (18.9)
Myocardial infarction 35 (3.3) 22 (6.2) 13 (1.8) 0.0001 11 (6.1) 11 (6.4) 5 (1.4) 8 (2.2)
Angina pectoris 121 (11.2) 44 (12.5) 77 (10.6) 0.37 23 (12.7) 21 (12.2) 39 (11.0) 38 (10.2)
Heart failure 83 (7.7) 34 (9.6) 49 (6.8) 0.1 17 (9.4) 17 (9.9) 21 (5.9) 28 (7.6)
Left ventricular hypertrophy 189 (17.5) 56 (15.9) 133 (18.3) 0.31 32 (17.7) 24 (14.0) 64 (18.1) 69 (18.6)
Aortic aneurysm 4 (0.4) 3 (0.9) 1 (0.1) 0.07 1 (0.6) 2 (1.2) 0 (0) 1 (0.3)
Arteriosclerotic peripheral arterial
occlusive disease
24 (2.2) 10 (2.8) 14 (1.9) 0.35 5 (2.8) 5 (2.9) 4 (1.1) 10 (2.7)
Serum creatinine outside normal range 73 (6.8) 68 (19.3) 5 (0.7) o0.0001 34 (18.8) 34 (19.8) 3 (0.9) 2 (0.5)
Proteinuria 126 (11.7) 69 (19.6) 57 (7.9) o0.0001 39 (21.6) 30 (17.4) 26 (7.3) 31 (8.4)
Previous type 2 diabetes, n (%) 578 (53.6) 173 (49.0) 405 (55.9) 0.03 85 (47.0) 88 (51.2) 197 (55.7) 208 (56.1)
Abbreviations: ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CKD, chronic kidney disease.
Data are number (%). P-value was calculated using w2 tests. CKD (þ ), patients with CKD at baseline; CKD ( ), patients without CKD at baseline; high-dose ARB, patients
allocated to high-dose ARB therapy; ARBþCCB, patients allocated to ARBþCCB combination therapy.
a
P¼ 0.03 versus high-dose ARB.
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ARB and 16 patients (9.3%; 33.9 per 1000 patient-years) of
172 patients assigned to ARB plus CCB combination
experienced primary events: the difference (56.1%) in relative
risk between the two groups was significant (hazard ratio
(HR)¼ 2.25; 95% confidence interval (CI)¼ 1.20–4.20;
P¼ 0.0096). On the other hand, in patients without CKD
(Figure 2b), there was no significant difference between high-
dose ARB and ARB plus CCB combination groups regarding
the incidence of primary events (27 (7.6%) vs. 32 (8.6%)
events: 28.8 per 1000 patient-years vs. 31.9 per 1000 patient-
years): HR¼ 0.89: 95% CI¼ 0.53–1.50; P¼ 0.6671.
Incidence of secondary end point in patients with or without
CKD
In patients with CKD (Figure 3a), the ARB plus CCB
combination group had a lower incidence of cerebrovascular
disease (HR¼ 3.45; 95% CI¼ 1.20–9.92; P¼ 0.0151) and
heart failure (HR¼ 9.27; 95% CI¼ 1.11–77.29; P¼ 0.0148)
than the high-dose ARB group.
On the other hand, in patients without CKD (Figure 3b),
there was no significant difference between the two treatment
groups with regard to any secondary end point.
Time course of changes in eGFR throughout the follow-up
period
Figure 4 depicts the time course of eGFR changes in the
subgroups with CKD or without CKD. In the subgroup with
CKD, compared with baseline eGFR, eGFR slightly declined
in both the high-dose ARB group and ARB plus CCB combi-
nation group during the follow-up period. eGFR (mean±
s.d.) at the end of the study tended to be lower in the high-
dose ARB group than in the ARB plus CCB combination
group (44.6±11.4 vs. 48.1±16.5ml/min per 1.73m2;
P¼ 0.291), although the difference did not reach statistical
significance. In the subgroup without CKD, eGFR at the endT
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Figure 1 | Time course of systolic and diastolic blood pressure
(BP) in high-dose angiotensin II receptor blocker (ARB) and ARB
plus calcium channel blocker (CCB) combination groups in
patients with chronic kidney disease (CKD) and without CKD.
(a) Indicates patients with CKD and (b) indicates patients without
CKD.
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of the study did not significantly differ between high-dose
ARB and ARB plus CCB combination groups (66.5±19.9 vs.
70.0±16.1ml/min per 1.73m2; P¼ 0.12), although eGFR
in the high-dose ARB group was significantly lower than that
in the ARB plus CCB combination group at 24 months
(66.8±13.4 vs. 70.6±15.0ml/min per 1.73m2; P¼ 0.01) and
30 months (65.2±14.2 vs. 69.9±15.9ml/min per 1.73m2;
P¼ 0.002).
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Figure 3 | Hazard ratios (HRs) and 95% confidence intervals (CIs) for the primary composite end points and secondary end points in
patients with chronic kidney disease (CKD) and patients without CKD at baseline. (a) Indicates patients with CKD and (b) indicates
patients without CKD. The HRs and 95% CIs were derived from a stratified Cox proportional hazards model, taking into account sex, age, and
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Figure 2 | Kaplan–Meier curves for primary composite end points during the follow-up period in patients with chronic kidney disease
(CKD) and without CKD. In (a), the number of patients in high-dose angiotensin II receptor blocker (ARB) and ARB plus calcium channel
blocker (CCB) combination groups were 181 and 172, respectively, and there were 30 and 16 primary end points in high-dose ARB and
ARB plus CCB combination groups, respectively. In (b), the number of primary end points was 27 in 354 patients assigned high-dose ARB
and 32 in 371 patients assigned ARB plus CCB combination. CI, confidence interval; HR, hazard ratio.
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Association of prognostic factors with primary outcome
events
Table 4 shows the results of multivariable Cox regression
analysis for overall patients, the subgroup with CKD, and the
subgroup without CKD. For overall patients, high-dose ARB
treatment was not significantly associated with primary
outcome events (P¼ 0.239), whereas sex (P¼ 0.004), age
(P¼ 0.001), and baseline cardiovascular disease (P¼ 0.042)
were significantly associated with primary outcome events.
In patients with CKD, high-dose ARB treatment (P¼
0.010), as well as age (P¼ 0.003), but not baseline cardio-
vascular disease (P¼ 0.304), was significantly associated with
primary outcome events. In patients without CKD, only sex
(P¼ 0.013) was associated with primary outcome events.
BP was not significantly associated with primary out-
come events for overall patients or patients with CKD or
without CKD.
Relationship between achieved BP and incidence of primary
events
Figure 5 indicates the adjusted relative risk at different levels
of achieved BP in overall patients with available eGFR data
(n¼ 1078). The incidence of primary events was significantly
higher in the subgroup with systolic BPX150mmHg
(HR¼ 3.50, 95% CI¼ 1.93–6.34, Po0.01) than that in the
subgroup with systolic BPo130mmHg. The incidence of
primary events was significantly higher in the subgroups that
achieved diastolic BP of 80–89mmHg (HR¼ 2.02, 95% CI¼
1.16–3.52, Po0.05) or diastolic BPX90mmHg (HR¼ 3.67,
95% CI¼ 1.36–9.90, Po0.05) compared with the subgroup
with diastolic BPo70mmHg.
Incidence of adverse events
The number of adverse events was 1, 3, 1, and 2 for
hyperkalemia; 7, 5, 5, and 3 for increase in serum creatinine;
1, 0, 1, and 2 for hypotension; and 2, 7, 8, and 13 for cancer
in the high-dose ARB/CKD, ARB plus CCB/CKD, high-dose
ARB/without CKD, and ARB plus CCB/without CKD
groups, respectively. There was no significant difference in
these adverse events between high-dose ARB and ARB plus
CCB groups, regardless of whether the patients had CKD.
DISCUSSION
The major findings of the current work were as follows: ARB
plus CCB combination therapy was more effective in the
prevention of cardiovascular morbidity and mortality for
Japanese elderly high-risk hypertensive patients with baseline
CKD compared with high-dose ARB therapy, whereas there
was no significant difference in the incidence of primary
events between these treatment groups for patients without
baseline CKD. Furthermore, we found that the treatment-
by-subgroup interaction between patients with CKD and
without CKD was significant. Our present findings provided
novel information indicating the superiority of ARB plus
Table 4 | Adjusted hazard ratios of prognostic factor for primary outcome events
Overall patients CKD (þ ) CKD ( )
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
High-dose ARB 1.26 (0.86–1.86) 0.239 2.27 (1.22–4.23) 0.010 0.86 (0.51–1.44) 0.561
Male gender 1.79 (1.21–2.64) 0.004 1.66 (0.92–3.01) 0.092 1.96 (1.15–3.34) 0.013
AgeX75 years 2.00 (1.35–2.97) 0.001 2.76 (1.40–5.43) 0.003 1.61 (0.96–2.71) 0.072
Previous CV disease 1.76 (1.02–3.04) 0.042 1.60 (0.65–3.95) 0.304 1.93 (0.96–3.85) 0.064
Previous diabetes 1.26 (0.81–1.94) 0.310 1.31 (0.68–2.52) 0.422 1.33 (0.73–2.43) 0.351
Abbreviations: ARB, angiotensin II receptor blocker; CKD, chronic kidney disease; CV, cardiovascular; HR, hazard ratio; 95% CI, 95% confidence interval.
CKD (þ ), patients with CKD at baseline; CKD ( ), patients without CKD at baseline; high-dose ARB, allocation to high-dose ARB therapy.
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filtration rate (eGFR) in patients with chronic kidney disease
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angiotensin II receptor blocker; CCB, calcium channel blocker. Data
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Figure 5 | Adjusted hazard ratios (HRs) and 95% confidence
intervals (CIs) of achieved systolic blood pressure (BP) and
diastolic BP levels for incidence of primary composite end points
in total patients with available estimated glomerular filtration
rate data (n¼ 1078). The achieved BP on a per-patient basis was
defined as the mean value of all BP values during the follow-up
period. The reference category was (a) o130mmHg for systolic
BP and (b) o70mmHg for diastolic BP. DBP, diastolic BP; SBP,
systolic BP.
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CCB combination over high-dose ARB in elderly hyper-
tensive high-risk patients with CKD at baseline.
Compelling evidence shows that reduced eGFR is an
independent risk factor for cardiovascular disease and all-
cause mortality in a wide range of populations,1,2,4–6 inclu-
ding the elderly3 and hypertensive patients.7 Generally, an
eGFR o60ml/min per 1.73mm2 is used as the cutoff value
for definition of CKD, because this level of eGFR is associated
with an increased prevalence of cardiovascular disease.11,23 In
the current study, almost all patients with CKD manifested
stage 3 CKD (eGFR of 30–59ml/min per 1.73mm2),
indicating that these patients had moderate renal dysfunc-
tion. In the OSCAR study, most of the primary events in
patients with CKD were cardiovascular events, although the
occurrence of deterioration of renal function was low, being
consistent with previous evidence that patients with CKD
have a much higher prevalence of cardiovascular disease than
of renal events.6 It is noteworthy that ARB plus CCB
combination therapy reduced the incidence of primary events
in patients with CKD more than did high-dose ARB, and
reduced the incidence of cerebrovascular disease and of
heart failure in patients with CKD more than high-dose
ARB. These observations demonstrate that ARB plus CCB
combination is superior to high-dose ARB in the prevention
of cardiovascular events in elderly high-risk hypertensive
patients with CKD. On the other hand, no difference in the
incidence of primary events was noted between the two
treatment groups in patients without CKD. Importantly,
there was a significant interaction between treatment groups
and CKD category. These findings provided evidence that
renal function significantly influences the effectiveness of
these two therapies on cardiovascular events in elderly
hypertensive patients. However, it cannot be completely
ruled out that the lack of difference in the incidence of
primary events between the two treatment groups in patients
without CKD might be attributed to an insufficient sample
size in the OSCAR study, because the number of patients in
the subgroup was relatively small.
Similar to the results with overall patients of the OSCAR
study,21 ARB plus CCB combination reduced BP more than
high-dose ARB both in patients with CKD and without CKD.
Furthermore, the proportion of patients who achieved target
BP was higher in the ARB plus CCB combination group than
in the high-dose ARB group, even though a higher percentage
of patients received additional antihypertensive drugs in
the high-dose ARB group. Our current findings are consistent
with the findings of a meta-analysis showing that the
combination of drugs from two different classes is more
effective in BP lowering than doubling the dose of one
drug.24
The present study did not allow us to define the precise
contribution of better BP control with ARB plus CCB
combination to the lower incidence of primary events in the
subgroup with CKD, because of the small number of patients
in this subgroup. Accumulating evidence indicates that strict
BP control is associated with the reduction of cardiovascular
events in a variety of populations with CKD.7,15 Large-scale
clinical studies25,26 demonstrate that lower BP is closely
associated with a lower incidence of stroke and heart disease.
Furthermore, the present analysis on the association of
achieved BP with the incidence of primary events shows that
lower BP is associated with lower incidence of primary
events, being consistent with previous evidence. In the
subgroup with CKD, eGFR during the follow-up period did
not significantly differ between the two treatment groups,
suggesting that the effect on renal function might not be
significantly different between the two treatments. Collec-
tively, it is likely that better BP control by ARB plus CCB
combination compared with high-dose ARB is responsible
for greater benefit of ARB plus CCB combination in
prevention of cardiovascular events in patients with CKD.
However, the Avoiding Cardiovascular Events through
Combination Therapy in Patients Living with Systolic
Hypertension (ACCOMPLISH) trial provided the evidence
that in patients with hypertension at high risk for cardio-
vascular events a RAS blocker plus CCB combination reduced
the progression of CKD,27 as well as cardiovascular morbidity
and mortality,28 more effectively than a RAS blocker plus
hydrochlorothiazide. Therefore, it cannot be completely
excluded that the BP-independent beneficial effect or renal
protective effect of ARB plus CCB combination might
partially contribute to the prevention of cardiovascular
events in patients with CKD.
Recently, we have reported the results of the OSCAR
study21 indicating that there was no significant difference
between ARB plus CCB combination and high-dose ARB in
the prevention of primary events in overall patients, although
ARB plus CCB combination reduced the incidence of
primary events in patients with baseline cardiovascular
disease more than high-dose ARB. Thus, our previous
report has revealed the superiority of ARB plus CCB combi-
nation over high-dose ARB in patients with baseline cardio-
vascular disease.21 In the current subanalysis, a greater
proportion of patients with CKD manifested coexisting
baseline cardiovascular disease compared with those without
CKD. Therefore, we further performed multivariable Cox
regression analysis for overall patients, and for patients with
CKD and without CKD. We found that allocation to high-
dose ARB, but not the presence of baseline cardiovascular
disease, was an independent prognostic factor for primary
outcome events in patients with CKD. Thus, CKD itself
contributes significantly to the superiority of ARB plus CCB
combination in prevention of cardiovascular events.
Study limitation
There are several study limitations for the present analysis.
First, it is well established that albuminuria, as well as
reduced eGFR, is an independent risk factor for cardio-
vascular disease and death.1–6,8–11 In the current study, we did
not examine urinary albumin excretion, because the primary
purpose of the OSCAR study was to examine the effect of the
two treatments on the incidence of cardiovascular events.
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Therefore, the precise effect of these two treatments on
renal function or the detailed role of renal function in the
incidence of primary events was not elucidated in the current
study. Second, the degree of sodium intake significantly
influences the effects of RAS blockers or CCB in patients with
CKD.29,30 However, in the OSCAR study, we did not mandate
salt restriction and did not monitor urinary sodium levels.
Therefore, we had no information on the amount of salt
intake in the OSCAR study. Third, in patients with CKD,
dosing time of antihypertensive drugs or the pattern of night-
time BP significantly affects the risk of cardiovascular
events.31 However, in this study, we did not have available
accurate information on when (in the morning or at night)
the patients took the medications, and did not take 24-h BP
measurements. Finally, it is unclear whether the present
findings on elderly hypertensive patients can be applied to
nonelderly hypertensive patients.
In conclusion, in Japanese elderly high-risk hypertensive
patients, ARB plus CCB combination therapy was more
effective in prevention of cardiovascular events in patients
with CKD compared with high-dose ARB therapy. It is likely
that better BP control with ARB plus CCB combination is
responsible for greater benefit of ARB plus CCB combination
in prevention of primary events. CKD defined by eGFR
contributes significantly to the relative effectiveness of ARB
plus CCB combination versus high-dose ARB in elderly
high-risk hypertensive patients. Our present work provided
novel insight into the antihypertensive strategy for patients
with CKD.
MATERIALS AND METHODS
The rationale, study design, treatment protocol, organization,
and management of the OSCAR study (see Appendix) have been
previously reported.21,22 In brief, the OSCAR study was a multi-
center prospective randomized open-label blinded end-point study
of 1164 hypertensive patients aged 65–84 years who had cardiovas-
cular disease (cerebrovascular disease, cardiac disease, vascular
disease, or renal dysfunction) and/or type 2 diabetes at baseline. In
the run-in period, all eligible patients received olmesartan (an ARB)
monotherapy at a dose of 20mg/day (a standard dose). If the target
BP control (o140/90mmHg) was not achieved by olmesartan
(20mg/day) monotherapy and the treatment was well tolerated,
patients were randomized to one of the two treatment arms, and
received either (1) a doubled dose (40mg/day) of olmesartan (high-
dose ARB monotherapy) or (2) a CCB (amlodipine or azelnidipine)
in addition to 20mg/day olmesartan (ARB plus CCB combination
therapy). If further additional antihypertensive treatment was
required to achieve the target BP, other antihypertensive drugs
such as diuretics or beta blockers could be added, but ARBs,
angiotensin-converting enzyme inhibitors, and CCBs were prohi-
bited. The follow-up period was 3 years. This study was conducted
under the Declaration of Helsinki and was approved by the
Institutional Review Board at each trial site. All patients gave
written informed consent.
The primary end point was the time to the first event.
The primary end-point events were a composite of fatal and
nonfatal cardiovascular events, including cerebrovascular disease
(cerebral infarction, cerebral hemorrhage, subarachnoid hemor-
rhage, unspecified stroke, and transient ischemic attack), coronary
artery disease (sudden death, myocardial infarction, angina
pectoris, and asymptomatic myocardial ischemia), heart failure,
other arteriosclerotic diseases (aortic aneurysm, aortic dissection,
and atherosclerotic diseases), diabetic microvascular complications
(neuropathy, retinopathy, and nephropathy), deterioration of renal
function (doubling of serum creatinine, end-stage renal disease as
defined by initiation of hemodialysis, or renal transplantation), and
noncardiovascular death. The secondary end points were incidence
of each cardiovascular event, BP change during the follow-up
period, and serious adverse events other than the primary end
points. The Endpoint Committee adjudicated, without knowledge
of the treatment assignment, all cases of cardiovascular events and
death.
Subgroup analysis according to eGFR
The subgroup analysis according to baseline eGFR was prespecified,
as described in our protocol paper.22 Baseline eGFR was calculated
for patients whose serum creatinine value at baseline was available.
The patients without serum creatinine data at baseline were
excluded from this analysis. In this study, eGFR was estimated
using the new three-variable Japanese equation,32 as follows:
eGFR (ml/min per 1.73m2 of body surface area)¼ 194serum
creatinine 1.094age 0.2870.739 (if female) instead of the abbre-
viated Modification of Diet in Renal Disease study equation.23 The
referenced equation used in this study is recommended for
estimation of GFR in Japanese patients, because eGFR calculated
by this equation has been demonstrated to be more accurate for
Japanese patients than that obtained by other equations.32 In this
study, CKD was defined as an eGFR ofo60ml/min per 1.73m2.11,23
The study population was divided into two groups based on baseline
eGFR: (1) patients with CKD (eGFR of o60ml/min per 1.73m2)
and (2) those without CKD (eGFR of X60ml/min per 1.73m2).
Statistical analyses
Sample size and power of the study were estimated as previously
described.22
Primary analyses were performed in compliance with the
intention-to-treat principle. For the primary end points, we
compared between groups using the log-rank test stratified by
sex, age, and risk factors. By using a stratified proportional hazards
model, the HR and 95% CI were calculated for each treatment
group. Time-to-first event curves were estimated by the
Kaplan–Meier method. Repeated measures analysis of variance was
used to compare between the groups for BP during the follow-up
period, and the least square method was used to estimate the mean
difference in BP between the groups. Time course of eGFR change
between groups was compared using the unpaired t-test adjusted by
Holm’s method to avoid multiplicity at multiple time points.
To estimate the heterogeneity of the HR for the prespecified CKD
category, the interaction between treatment group and CKD
subgroup was assessed using the interaction terms in a stratified
Cox proportional hazards model.
Multivariable Cox proportional hazards analyses were performed
to determine the association of each prognostic factor with the
incidence of primary outcome events, adjusted for the following
covariates: sex, age, treatment group, baseline cardiovascular disease,
baseline diabetes, and adjusted for systolic BP for a time-dependent
covariate.
The achieved systolic BP and diastolic BP were classified into
four levels: systolic BP:o130, 130–139, 140–149, andX150mmHg;
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diastolic BP:o70, 70–79, 80–89, and X90mmHg. Adjusted HRs
and 95% CIs were calculated using the multiple Cox proportional
hazard model adjusted by sex, age, baseline cardiovascular disease,
and diabetes.
For all analyses, the overall significance level was determined as
5%, and two-sided tests were used.
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